New Round Of Drug Maker Consolidation Expected In Japan
This article was originally published in PharmAsia News
Executive Summary
Japan's drug-making industry anticipates a new spurt of consolidation moves as previous capital investments cause companies charge off increasing amounts of depreciation. The generics part of the industry in Japan is estimated to be using only a little more than half its production capacity as a result of firms expanding capacity ahead of expected market growth. That situation is expected to make small and midsize firms exposed as targets for acquisition, particularly in the eyes of Indian drug makers. But large Japanese firms also are beginning to buy their smaller cousins. (Click here for more - a subscription may be required